A review of JAK and IL-23 inhibitors to treat vitiligo.
Australas J Dermatol
; 64(2): 204-212, 2023 May.
Article
em En
| MEDLINE
| ID: mdl-36810815
ABSTRACT
Vitiligo is an autoimmune skin disorder resulting in the depigmentation of skin characterised by patches of varying sizes and shapes. A common disorder of pigmentation that affects 0.5%-2% of the global population. Despite its well-understood autoimmune pathogenesis, the targets for effective cytokine intervention remain unclear. Current first-line treatments include oral or topical corticosteroids, calcineurin inhibitors and phototherapy. These treatments are limited, have varying efficacies, and are associated with significant adverse events or can be time-consuming. Therefore, biologics should be explored as a potential treatment for vitiligo. There are currently limited data for the use of JAK and IL-23 inhibitors for vitiligo. A total of 25 studies were identified in the review. There is promising evidence regarding the use of JAK and IL-23 inhibitors for the treatment of vitiligo.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Vitiligo
/
Fármacos Dermatológicos
Limite:
Humans
Idioma:
En
Revista:
Australas J Dermatol
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Austrália